Advaxis cervical-cancer drug gets orphan designation

|About: Advaxis Inc. (ADXS)|By:, SA News Editor

Advaxis' (ADXS) ADXS-HPV immunotherapy treatment for Stage II-IV invasive cervical cancer has received Orphan Drug Designation from the FDA.

ADXS-HPV has already generated encouraging Phase 2 data.

Shares are +8.5%. (PR)